Specifically, targeting Fbxo22 can be taken as a promising strategy for cancer therapy, since the inhibitory role of Fbxo22 has been proved in different malignancies, including breast cancer (Cheng et al. 2020). This evidence concerns the gene FBXO22 and breast carcinoma.